Name: Anti-Mouse PD-1 In Vivo Antibody - Ultra Low Endotoxin (RMP1-14)
Price: 832.00 USD

- Overview
  - Antigen Distribution: Subset of double negative thymocytes, activated T and B cells
    Specificity: Anti-PD-1 In Vivo Antibody - Ultra Low Endotoxin (RMP1-14) recognizes an epitope on Mouse PD-1
    Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
    Isotype Control: Rat IgG2a In Vivo Isotype Control - Ultra Low Endotoxin [1-1] (ICH2244UL)
    Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method
    Aggregation: Aggregation level ≤ 1%
    
    Please contact us at for specific academic pricing.
    
    Background
    
    CD279, also known as programmed death-1 (PD-1) is a 50-55 kD immunoglobulin superfamily member. PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells. The PD-1 ligands, PD-L1 (also known as B7-H1) and PD-L2 (B7-DC), are members of the B7 immunoglobulin superfamily. This RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production.
- Properties
  - Host
    
    rat
    
    Isotype
    
    IgG2a kappa
    
    Reactivity
    
    mouse
    
    Clone
    
    RMP1-14
    
    Immunogen
    
    Mouse PD-1 transfected BHK cells
    
    Purification
    
    >98% by SDS-PAGE and HPLC
    
    Formulation
    
    0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium or preservatives added.
    
    Storage
    
    anti-PD-1 In Vivo Antibody - Ultra Low Endotoxin (RMP1-14) is stable when stored at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
    
    Molecular Weight
    
    ≥ 2.0 mg/ml
    
    Regulatory Status
    
    Blocking: Clone RMP1-14 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1. For immune checkpoint antibodies 200 ug per mouse per injection is the standard dosage in the literature. For this anti-PD-1 (clone RMP1-14), we suggest to inject 200 ug/mouse ip generally on days 3, 6 and 9, post injection of tumor. Sometime up to six injections depending on the length of the experiment may be required.
    Each investigator should determine their own optimal working dilution for specific applications.
    
    Antigen
    
    (Gene ID:Programmed cell death protein 1, Pdcd1, CD279)
    
    * Products are for research use only. Not for use in diagnostic or therapeutic procedures.
- Applications
  - Application
    
    WB; Blocking; Flow Cytometry; Functional Assays
- Reference
  - Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

Anti-Mouse PD-1 In Vivo Antibody - Ultra Low Endotoxin (RMP1-14)

Anti-Mouse PD-1 In Vivo Antibody - Ultra Low Endotoxin (RMP1-14)

Background

We Also Recommend

Anti-Mouse IFN alpha In Vivo Antibody - Ultra Low Endotoxin (TIF-3C5)

Anti-Mouse PD-1 (RMP1-14) - Ultra Low Endotoxin 5mg/ml

Anti-Mouse Tim-3 In Vivo Antibody - Ultra Low Endotoxin (RMT3-23)